HLX71
/ Fosun Pharma, Shanghai Henlius Biotech
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
April 01, 2022
Evaluate the Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of HLX71 (Recombinant Human Angiotensin-converting Enzyme 2-Fc Fusion Protein for COVID-19) in Healthy Adult Subjects
(clinicaltrials.gov)
- P1 | N=32 | Completed | Sponsor: Hengenix Biotech Inc | Not yet recruiting ➔ Completed | Trial primary completion date: Apr 2021 ➔ Jul 2021
Trial completion • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • ANGPT1 • CRP
October 12, 2020
Evaluate the Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of HLX71 (Recombinant Human Angiotensin-converting Enzyme 2-Fc Fusion Protein for COVID-19) in Healthy Adult Subjects
(clinicaltrials.gov)
- P1; N=40; Not yet recruiting; Sponsor: Hengenix Biotech Inc
Clinical • New P1 trial • Infectious Disease • Novel Coronavirus Disease
1 to 2
Of
2
Go to page
1